Allen
Business Research
ArgenX
Belgium
Biography
Allen was responsible for the 1999 license agreement with Human Genome Sciences that led to the discovery of the antibody drug BENLYSTA®(belimumab), now approved for the treatment of systemic lupus erythematosus. Prior to joining argenx, Dr. Allen acted as an independent consultant to around 25 emerging biotech companies, providing strategic management and business development support.
Research Interest
Business Research
